Skin Tech Pharma Group S.L.

Skin Tech Pharma Group S. L. , located in Girona, Spain, specializes in advanced solutions for aesthetic medicine, offering a wide range of innovative products and services for medical professionals globally. Founded in 1996 in Girona, Spain, Skin Tech Pharma Group S.

L. develops and distributes aesthetic medical products. The company, led by CEO Philippe Deprez, has engaged in one funding deal, with the most recent occurring on June 21, 2024. Skin Tech Pharma Group S.

L. specializes in advanced solutions in aesthetic medicine through a range of products and services designed for medical professionals. Their core offerings include a variety of medical devices, chemical peelings, injectables, and biorevitalization products that cater to the needs of aesthetic practitioners and their clients. The company emphasizes innovative techniques and scientific understanding in their educational programs, having successfully conducted over 500 courses and workshops, equipping around 2,000 members from 85 countries with the latest knowledge in the field.

Their products are distributed globally, addressing the needs of aesthetic medicine practitioners in diverse markets, including Western Europe, Asia, and parts of the Americas, ensuring that they meet a significant portion of the global aesthetic demands. Skin Tech Pharma Group S. L. generates revenue primarily through direct sales of its products and educational services, reaching USD 19.

14 mn in revenue for the year 2023. The company engages in B2B transactions with aesthetic clinics, medical professionals, and distributors, allowing for strategic partnerships in various regions. Their product line includes well-recognized offerings such as RRS® HA Long Lasting and Skin Tech® brands, which are positioned at premium pricing tiers within the market. The EBITDA for 2023 was USD 9.

86 mn, supplemented by educational workshops and training sessions, facilitating continuous engagement and customer loyalty. Skin Tech Pharma Group S. L. plans to utilize the investment from Charterhouse Capital Partners, made on June 21, 2024, to support its strategy for entering new markets and enhancing product offerings.

The company aims to expand into additional regions, targeting specific markets in Asia and the Americas by the end of 2025. This funding will bolster their operational capabilities, thus encouraging natural growth and product development initiatives.